PURPOSE: 2-Nitro-alpha-[(2,2,2-trifluoroethoxy)methyl]-imidazole-1-ethanol (TF-MISO) was investigated as a potential noninvasive marker of tissue oxygen levels in tumors using (19)F magnetic resonance spectroscopy (MRS) and (19)F chemical shift imaging. EXPERIMENTAL DESIGNS: In vitro data were obtained using high-performance liquid chromatography on tumor cells incubated under varying oxygen conditions to determine the oxygen-binding characteristics. In vivo data were obtained using a well-characterized hypoxic murine breast tumor (MCa), in addition to studies on a rat prostate tumor model (R3327-AT) implanted in nude mice. Detection of intratumor (19)F signal from TF-MISO was done using MRS for up to 10 h following a 75 mg/kg i.v. injection. Localized distribution of the compound in the implanted MCa tumor has been imaged using slice-selective two-dimensional chemical shift imaging 6 h after injection. RESULTS: The in vitro results showed that TF-MISO preferentially accumulates in cells incubated under anoxic conditions. The in vivo (19)F MR spectral features (line width and chemical shift) were recorded as a function of time after injection, and the results indicate that the fluorine atoms are indeed sensitive to changes in the local environment while still providing a detectable MR signal. Ex vivo spectra were collected and established the visibility of the (19)F signal under conditions of maximum hypoxia. Late time point (>6 h) tumor tissue concentrations, as obtained from (19)F MRS, suggest that TF-MISO is reduced and retained in hypoxic tumor. The feasibility of obtaining TF-MISO tumor distribution maps in a reasonable time frame was established. CONCLUSIONS: Based on the results presented herein, it is suggested that TF-MISO has the potential to be a valid magnetic resonance hypoxia imaging reporter for both preclinical hypoxia studies and hypoxia-directed clinical therapy.
PURPOSE:2-Nitro-alpha-[(2,2,2-trifluoroethoxy)methyl]-imidazole-1-ethanol (TF-MISO) was investigated as a potential noninvasive marker of tissue oxygen levels in tumors using (19)F magnetic resonance spectroscopy (MRS) and (19)F chemical shift imaging. EXPERIMENTAL DESIGNS: In vitro data were obtained using high-performance liquid chromatography on tumor cells incubated under varying oxygen conditions to determine the oxygen-binding characteristics. In vivo data were obtained using a well-characterized hypoxic murinebreast tumor (MCa), in addition to studies on a ratprostate tumor model (R3327-AT) implanted in nude mice. Detection of intratumor (19)F signal from TF-MISO was done using MRS for up to 10 h following a 75 mg/kg i.v. injection. Localized distribution of the compound in the implanted MCa tumor has been imaged using slice-selective two-dimensional chemical shift imaging 6 h after injection. RESULTS: The in vitro results showed that TF-MISO preferentially accumulates in cells incubated under anoxic conditions. The in vivo (19)F MR spectral features (line width and chemical shift) were recorded as a function of time after injection, and the results indicate that the fluorine atoms are indeed sensitive to changes in the local environment while still providing a detectable MR signal. Ex vivo spectra were collected and established the visibility of the (19)F signal under conditions of maximum hypoxia. Late time point (>6 h) tumor tissue concentrations, as obtained from (19)F MRS, suggest that TF-MISO is reduced and retained in hypoxic tumor. The feasibility of obtaining TF-MISO tumor distribution maps in a reasonable time frame was established. CONCLUSIONS: Based on the results presented herein, it is suggested that TF-MISO has the potential to be a valid magnetic resonance hypoxia imaging reporter for both preclinical hypoxia studies and hypoxia-directed clinical therapy.
Authors: Roman V Shchepin; Lamya Jaigirdar; Thomas Theis; Warren S Warren; Boyd M Goodson; Eduard Y Chekmenev Journal: J Phys Chem C Nanomater Interfaces Date: 2017-12-01 Impact factor: 4.126
Authors: Terence P F Gade; Jason A Koutcher; William M Spees; Bradley J Beattie; Vladimir Ponomarev; Michael Doubrovin; Ian M Buchanan; Tatiana Beresten; Kristen L Zakian; H Carl Le; William P Tong; Philipp Mayer-Kuckuk; Ronald G Blasberg; Juri G Gelovani Journal: Cancer Res Date: 2008-04-15 Impact factor: 12.701
Authors: Eduard Y Chekmenev; Siu-Kei Chow; Daniel Tofan; Daniel P Weitekamp; Brian D Ross; Pratip Bhattacharya Journal: J Phys Chem B Date: 2008-04-19 Impact factor: 2.991
Authors: Praveen K Gulaka; Federico Rojas-Quijano; Zoltan Kovacs; Ralph P Mason; A Dean Sherry; Vikram D Kodibagkar Journal: J Biol Inorg Chem Date: 2013-11-27 Impact factor: 3.358
Authors: Ligang Xing; Xuelong Deng; Khushali Kotedia; Ellen Ackerstaff; Vladimir Ponomarev; C Clifton Ling; Jason A Koutcher; Gloria C Li Journal: Acta Oncol Date: 2008 Impact factor: 4.089
Authors: Thomas Theis; Nuwandi M Ariyasingha; Roman V Shchepin; Jacob R Lindale; Warren S Warren; Eduard Y Chekmenev Journal: J Phys Chem Lett Date: 2018-10-10 Impact factor: 6.475
Authors: C P Lee; G S Payne; A Oregioni; R Ruddle; S Tan; F I Raynaud; D Eaton; M J Campbell; K Cross; G Halbert; M Tracy; J McNamara; B Seddon; M O Leach; P Workman; I Judson Journal: Br J Cancer Date: 2009-12-01 Impact factor: 7.640